LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and nine months ended September 30, 2008.
